Bruce, Their was no doubt in my mind that the t
Post# of 15624
(Total Views: 494)
Posted On: 09/15/2017 12:23:09 AM
Bruce,
Their was no doubt in my mind that the trial had started, but what we don't know is about expanding it, and if they did expand it as we've been told by investors who spoke with people there, have they finished, or are they still adding patients. I don't see how the statement clarified that.
As I remember the trial protocol, all participants are observed for 60 days minimum. If we knew they were no longer enrolling participants we'd know the trial would be over in 60 days, or less. I can't say that from the statement.
If the company did update the clinical trials database, even though the trial is being done in Israel, I believe they'd have updated the database when they initiated enrollment, they'd have modified the trial if they were adding additional participants, and would have indicated that the trial was fully enrolled as well as indicating a change to the target completion date. Finally they would indicate the trial was concluded, and shortly thereafter they'd have been able to announce top line data. The complete trial results wouldn't be available to investors until they'd been submitted somewhere for peer review.
My point is that much could be communicated, but practically nothing has been. This isn't a case where they must do it, but it's an option they could take, but one they chose not to.
Gary
Their was no doubt in my mind that the trial had started, but what we don't know is about expanding it, and if they did expand it as we've been told by investors who spoke with people there, have they finished, or are they still adding patients. I don't see how the statement clarified that.
As I remember the trial protocol, all participants are observed for 60 days minimum. If we knew they were no longer enrolling participants we'd know the trial would be over in 60 days, or less. I can't say that from the statement.
If the company did update the clinical trials database, even though the trial is being done in Israel, I believe they'd have updated the database when they initiated enrollment, they'd have modified the trial if they were adding additional participants, and would have indicated that the trial was fully enrolled as well as indicating a change to the target completion date. Finally they would indicate the trial was concluded, and shortly thereafter they'd have been able to announce top line data. The complete trial results wouldn't be available to investors until they'd been submitted somewhere for peer review.
My point is that much could be communicated, but practically nothing has been. This isn't a case where they must do it, but it's an option they could take, but one they chose not to.
Gary
(0)
(0)